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Summary 24 
Objective: Lower extremity peripheral arterial disease (PAD) is a chronic condition most 25 
commonly presenting with intermittent claudication (IC). IC limits walking ability and may 26 
negatively affect health-related quality of life. Treadmill assessment of maximal walking 27 
distance (MWD) is the gold standard to assess PAD symptom severity.  Despite being a well-28 
established and reproducible tool, it may be inappropriate (due to frailty or fear) for some 29 
patients and only describes maximal abilities for a single walk test.  Global Positioning 30 
Systems (GPS) have been proposed as reliable and reproducible tool to measure total, mean 31 
and maximal walking distances in PAD patients, in the community setting. Using GPS our 32 
study attempted to explore what happens to the walking ability of patients with IC following 33 
no intervention under "real-life" conditions. 34 
Design and Methods: Using the GlobalSat DG100 GPS, forty-three patients (69±9yrs; 9 35 
female; no invasive interventions or rehabilitation) undertook two 60-minute walking 36 
assessments, 6 months apart. Assessments took place in community spaces that had even 37 
terrain, no tall trees or buildings and were free from motorised vehicles. GPS-measured 38 
maximum walking distance was the main study outcome measure. 39 
Results: Over the 6-month period, patients demonstrated significantly shorter GPS-40 
measured, mean (552m vs 334m; p=0.02) and maximum (714m vs 545m; p=0.04) walking 41 
distances, stopping also more frequently (9 v 5 times; p=0.03).   42 
Conclusions: Given the reported symptom progression we advocate early intervention (e.g. 43 
exercise interventions) combined with frequent patient monitoring in attempts to maintain 44 
or improve walking ability. 45 
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 48 
INTRODUCTION  49 
Peripheral arterial disease (PAD) is a disease caused by atherosclerosis, resulting in 50 
narrowing of the arteries, characterised by obstruction of blood flow in the arteries 51 
supplying the lower limbs. PAD prevalence increases with age, reaching 25% for individuals 52 
over the age of 75 years of age (Fowkes et al., 2013).  The majority of symptomatic patients 53 
with PAD experience intermittent claudication (IC) (Vodnala et al., 2010). IC is defined as a 54 
pain or discomfort that occurs during walking due to insufficient blood flow increase, 55 
limiting walking ability (Norgren et al., 2017), which negatively affects patients' health-56 
related quality of life (Regensteiner et al., 2008).   57 
 58 
The limiting walking ability is measured by “claudication distance” (e.g. the distance walked 59 
at the onset of claudication pain) and by “maximal walking distance” (MWD), which is 60 
defined as the absolute maximum distance walked before limb discomfort or pain forces the 61 
patient to stop. Reduced walking ability has been associated with increased mortality (due 62 
mainly to cardiovascular disease) (Mcdermott et al., 2008), which may reach 30% over a 5-63 
year period (Golomb 2006). Interventions designed to improve walking ability can reduce 64 
this morbidity and mortality; Interventions need to be patient-centred to maximise 65 
compliance. 66 
 67 
4 
 
Tools used to assess walking ability, include treadmill walking test (Duprez et al., 1999), 4- or 68 
6-minute walking tests (Collins et al., 2010) or questionnaires (e.g. walking impairment 69 
questionnaire (WIQ) (Ouedraogo et al., 2011), Walking Estimated Limitation Calculated by 70 
History (WELCH) questionnaire (Myers et al., 2008). The two questionnaires have been 71 
shown to have high correlation with the 6-minute walking test (Gernigon et al., 2015) and 72 
treadmill walking assessments (Ouedraogo et al., 2011).   These tools however, may not 73 
reflect accurately the true walking impairment or may be inappropriate for older or frailer 74 
patients). These tests also fail to give an indication of the patients' walking ability under 75 
"real" conditions - such as walking that takes place in the community, and don't give 76 
information about walking speed or the number of stops between walking episodes. Global 77 
Positioning Systems (GPS) have been proposed as reliable, reproducible tools to measure 78 
total, mean and maximal walking distances in patients with PAD in community settings 79 
(Gernigon et al., 2015).  80 
 81 
Although patients with IC have been the focus of a large number of studies (Bauman & 82 
Arthur 1997, Nicolaï et al., 2012, Klonizakis et al., 2016), the natural history of walking ability 83 
under "real-life" settings is largely understudied and poorly understood. We therefore 84 
wanted to study what happens to the walking ability of patients with IC using GPS in 85 
patients not receiving any intervention following a 6-month period. We hypothesised that 86 
the condition caused a deterioration in MWD of patients, over a 6-month period. 87 
 88 
MATERIALS AND METHODS 89 
The present study was approved by South Yorkshire NHS Research Ethics Committee 90 
(13/YH/0088). This research was carried out in accordance with the Declaration of Helsinki 91 
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of the World Medical Association and all participants gave their written informed consent to 92 
participate. 93 
 94 
Forty-three adult men and women with clinically-diagnosed IC due to PAD were identified 95 
from vascular clinic attendance lists stored at the Sheffield Vascular Institute, Northern 96 
General Hospital, Sheffield (Table 1) between 2013-2016. All participants completed all 97 
designated study visits. The sample size was estimated (with MWD being the main outcome 98 
measure), based on the number required on previous studies from authors in our group 99 
undertaken on the same population (Gernigon et al., 2015). All participants had stable IC 100 
(4.4 (3.1) years’ duration), with a condition’s duration ranging between 8 months and 11 101 
years. Patients with critical limb ischaemia, with uniquely impaired walking ability (e.g. 102 
wheelchair-bound patients and patients with lower-extremity amputation), with recent 103 
major surgery in the previous 6 months, with heart failure of New York Heart Association 104 
grade III or IV, with known severe respiratory disease other than obstructive sleep apnoea, 105 
who were pregnant at the time and those with Parkinson's disease, hemiplegia or 106 
paraplegia or who were in an exclusion period due to participation in other research studies 107 
were excluded from the study. Participants did not receive an incentive to take part in the 108 
study, with an exception of free parking at the laboratory premises, during assessment days. 109 
All participants were receiving medical treatment (e.g. pharmacotherapy) at the time of 110 
their participation in the study, as per their individual circumstances, being also followed by 111 
their General Practitioners and by physicians within hospital vascular clinics. No MI or stroke 112 
or death incident took place within the study period for any of our participants. 113 
 114 
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All patients attended the Centre for Sport and Exercise Science (CSES) of Sheffield Hallam 115 
University for an initial consultation session during which they were screened by a Vascular 116 
Consultant. Patients were familiarised with the study protocol and provided written 117 
informed consent.  118 
 119 
During the second visit, participants completed the following clinical questionnaires: SF-36 120 
(Ware & Sherbourne 1995), WIQ (Myers et al., 2008) and WELCH (Ouedraogo et al., 2011). 121 
They completed a standardised treadmill walking test [16], with a constant walking speed of 122 
3.2 km/h with a gradient of 10% for 15 minutes. All tests ended when participants could no 123 
longer walk despite sustained encouragement or after 15 minutes. Twelve-lead 124 
electrocardiogram monitoring with ST segment analysis was performed continuously 125 
(Cardioperfect, Welch Allyn, USA) with termination of walk testing if the participant 126 
developed angina symptoms or developed ST depression equal or greater than 2mm in any 127 
lead. All participants completed the clinical questionnaires retrospectively via post, after 128 
their second community-based walking assessment.  129 
 130 
Community-based walking assessment 131 
Walking capacity was assessed in the community using a commercially-available global 132 
positioning system (GPS) data logger (DG-100 GPS data logger and the AT-65 GPS Active 133 
Antenna, GlobalSat Technology Corp., New Taipei City, Taiwan), as previously described 134 
(Faucheur et al., 2010). Community-based walking assessments took place on two 135 
occasions: once following their laboratory visit, and the second 6 months after their first 136 
community-based assessment. The walking assessment lasted 60-65 minutes in total, on 137 
each occasion. The device was worn above their outermost clothing layer. It was 138 
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emphasised to the participants that the aim of this unconstrained walking was to reproduce 139 
their daily walking limitation during an outdoor, unsupervised, walk at their usual pace. 140 
Participants were also encouraged to undertake a short "test" walk, prior to their main 141 
walking assessment, in order to familiarise themselves with the equipment. Patients were 142 
given a leaflet with detailed instructions, and were given a detailed demonstration of the 143 
equipment use being also instructed to: 144 
a) avoid undertaking the assessment during adverse weather conditions (e.g., heavy rain, 145 
high wind, snow), 146 
b) wait for ≥10 minutes on arrival at the self-chosen, flat, open space to allow for 147 
initialisation of the system. This duration is greater than twice the maximal time required for 148 
satellite detection and avoids adding the effects of previous walks to the recorded MWD, 149 
c) walk at their usual walking speed for at least 45 minutes, including rest periods, 150 
d) stop at maximal claudication pain rather than voluntarily slowing down to avoid pain 151 
when walking discomfort occurs (onset of pain). No recommendation was provided about 152 
the duration of the stops.  153 
e) wait for an additional 10 minutes at the end of the 45-minute walk before switching off 154 
the GPS device. This allowed the research team to detect the end of the walking period. 155 
While doing assessments, patients had access to technical support on the use of the device. 156 
On return of the device, the walking data was downloaded and analysed to determine the 157 
patients’ walking speed, distances of interest and the duration of rest periods. The 158 
maximum walking distance was identified from the longest distance period of continuous 159 
walking (but not the last boot).  160 
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Patients’ community-based walking ability was analysed as soon as possible after receipt of 161 
the GPS dataloggers. In 2 cases of poor signal quality or non-interpretable/missing data 162 
patients were asked to repeat the relevant test.  163 
Information collected included: MWD, minimum (defined as the minimum walking distance 164 
walked between complete stops on each walk) and mean walking distance (defined as the 165 
average walking distance walked between complete stops for each walk), the number of 166 
stops, total walking time, the average walking speed and recovery time (defined as the 167 
time required for a participant to resume walking following a complete stop).  168 
 169 
Statistical Analysis  170 
Outcome measures were assessed for normal distribution using the Kolmogorov–Smirnov 171 
goodness-of-fit test. As they were normally distributed, the student paired t test was 172 
performed to compare results between visits. Statistical analyses were performed with 173 
SPSS (V17.0.0 SPSS Inc., 2008). For all statistical tests, a two-tailed probability level of p 174 
< .05 was used to indicate statistical significance. Data are expressed as mean (Standard 175 
Deviation; SD). 176 
 177 
RESULTS  178 
Treadmill Walking Assessment – Questionnaire-based Walking Measurements 179 
Study participants reported diminished health-related quality of life (i.e., 30.5 (6.6) for 180 
Physical Component Summary and 35.7 (7.5) for Mental Component Summary), as assessed 181 
by SF-36 health-related quality of life questionnaire (Table 2). Similarly, they had low 182 
walking capacity, as assessed using treadmill-walking test (355 (268)) and questionnaires 183 
(i.e. 24.5 (9.6) for WIQ distance sub-score and 26% (22%) for WELCH). Both their health-184 
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related quality of life and WELCH-assessed walking ability were reduced significantly 185 
following their 2nd questionnaire-based assessment (Table 2). No treadmill follow-up 186 
assessments were conducted due to operational reasons. 187 
 188 
Community Walking Assessment 189 
Study participants walked a shorter total distance on the second occasion (2273 (460) 190 
m vs 2345 (478) m on the first), although this difference did not reach statistical 191 
significance (p=0.4).  192 
However, mean- (552 (112) m vs 334 (78) m; p=0.02) and maximum- walking distance 193 
(714 (150) m vs 545 (123) m; p=0.04) were significantly reduced over the 6-month 194 
period (Figure 1). Similarly, study participants stopped more frequently during their 2nd 195 
walk (number of stops being 7(5) vs 9(5) for 1st and 2nd walk respectively; p=0.03).  196 
On the other hand, participants: 197 
i) Walked for a similar time on both occasions (49 (13) on the first occasion vs 198 
49 (11) 6 months later; p=0.96),  199 
ii) walked at a similar speed (3.49 (1) km/h on first occasion vs 3.45 km/h (1) 6 200 
months later; p=0.81) and 201 
iii) had a similar mean recovery time (1.42 (1) minutes on the first occasion vs 202 
1.27 (1.26) minutes on the second occasion; p=0.57).  203 
 204 
DISCUSSION 205 
Although treadmill walking assessments are considered as the "gold standard" 206 
measurement of walking impairment in PAD patients with IC (Gernigon et al., 2015), 207 
having the highest levels of reproducibility and reliability (Nicolaï et al., 2012) they suffer 208 
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from a number of disadvantages. They can be costly (as in most of circumstances they 209 
are conducted under physician supervision in a hospital environment), have poor 210 
availability, are time-consuming and repeat testing may be less frequent than desirable 211 
due to service restraints and equipment/personnel availability. Additionally, treadmill 212 
assessments may not be appropriate for some participants who are older, frail and 213 
without exercise/treadmill walking experience. Consequently, it is possible that 214 
measurements may not be representative of the true degree of IC in this sub-group of 215 
PAD patients or measure “real-life” walking. 216 
GPS has been proven to offer a reliable assessment of IC patients' walking ability 217 
allowing testing to occur in conditions as close as possible to a usual walk (Gernigon et 218 
al., 2015; Gernigon et al., 2015b). Although some critique exists in regards to 219 
equipment cost and time needed to explain procedures to patients and to analyse 220 
findings (Lejay et al., 2015), the benefits may supersede the disadvantages, even though 221 
additional testing of such devices may be necessary, in larger cohorts (Gernigon et al., 222 
2015; Faucheur et al., 2010). 223 
 224 
Our study is the first to report a statistically- and clinically- significant deterioration in 225 
the community (GPS- assessed) maximum and mean walking distance (Figure 1) in 226 
patients with established IC, who have not received either an invasive (e.g. surgical) 227 
treatment or followed a formalised exercise intervention or had a modified treatment. 228 
The importance of the finding becomes more significant, considering that : a) the total 229 
walking time remained similar while the number of stops was increased between walks 230 
and b) patients' health-related quality of life assessment was already significantly 231 
affected at the time of the first visit (Table 2), which would have been at least 8 months 232 
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since they have been originally diagnosed with IC, an amount of time sufficient for them 233 
to adapt to their new life circumstances.   It is also important to note that our baseline, 234 
health-related quality of life findings are similar to those reported in other studies, 235 
where improvements were only noted following structured (home or supervised) 236 
exercise programmes or surgery [Jakubsevičienė et al., 2014; Prévost et al., 2015). 237 
 238 
Therefore, the significant change in walking patterns (confirmed by WELCH) within a 6-239 
month time-period is likely to have substantial negative effect on activities of daily 240 
living, patients’ life choices (as it was confirmed by SF-36 questionnaires) and 241 
compliance to exercise programmes that these patients may be referred to (with 242 
compliance being a common problem on most exercise programmes for IC patients (Al-243 
Jundi et al., 2013; Gommans et al., 2013). This may in turn impact further their health-244 
related quality of life and disease progression.  245 
 246 
The National Institute for Health and Care Excellence (NICE) guidelines in the U.K. – as it 247 
is the case in most Western countries - recommend a trial of supervised exercise for all 248 
patients with IC, prior to any, more invasive, treatment (NICE guidelines 2017). As this 249 
however, is not available in most clinical units, in many cases standard practice is 250 
restricted in monitoring of the patient's condition in relatively infrequent hospital 251 
appointments and the advice provision to "go home and walk as much as possible” (Al-252 
Jundi et al., 2013). Our study demonstrates – being in agreement with recent 253 
aggregating publications (Al-Jundi et al., 2013; Gommans et al., 2013)- that this is not 254 
sufficient, as there are significant changes in walking patterns, manifested by more 255 
frequent stops and lower maximum walked distance (714m vs 545m; p=0.04) (Figure 1) 256 
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using a real-life walking assessment in this patient group.  It may, therefore, be 257 
necessary for rehabilitation referrals to occur earlier in disease course and a different 258 
approach to earlier treatment be implemented, which would include patient monitoring 259 
using “real-life”, community-based (e.g. GPS) walking assessments. Our results certainly 260 
emphasise the need to provide a timely exercise intervention, otherwise we risk 261 
demotivating patients resulting in poor compliance and quality of life: It is worth noting 262 
that the study participant with the worst deterioration in MWD required a more 263 
invasive surgical intervention.   264 
 265 
Study limitations 266 
Due to original study design constraints it was not possible to repeat treadmill 267 
measurements. Although the focus of the study was to monitor community based 268 
walking and demonstrate the utility of GPS systems in this patient group, we 269 
acknowledge that the lack of repeated treadmill assessments might have influenced our 270 
ability to draw safer conclusions from this study. Finally, it may be considered that the 271 
changes in walking patterns are due to additional effort made by our participants to 272 
fulfil what they perceived as the study team’s expectations of their walking ability. We 273 
however, believe that this is not the case, as our participants were instructed to treat 274 
the assessment as one of their “normal” walks, the equipment used for the assessment 275 
caused- due to its small size - minimal discomfort and there was a 6-month gap 276 
between assessments, which made it very difficult for the participants to remember the 277 
distance that they originally covered, especially as they were unaware of the actual 278 
distance values of their assessment.  279 
 280 
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Conclusions 281 
Given the marked changes in walking patterns revealed by our study, we suggest 282 
modifications to clinical strategies in this patient group to maintain function and 283 
optimise walking ability. This could be a combination of more frequent patient 284 
monitoring (including community-based assessments with GPS or other similar 285 
methods/tools) and rehabilitation (with the preference being for supervised exercise 286 
sessions as recommended by the American College of Cardiology  (Rooke et al., 2011) 287 
and/or home-exercise programmes; Gommans et al., 2013).   288 
Our findings strengthen the viewpoint that GPS technology can help clinicians in the 289 
monitoring of ‘real world’ walking ability in this patient group and may support the 290 
decision-making process for their future therapeutic pathways.  291 
 292 
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TABLES  401 
Gender Allocation 34 men, 9 women 
Age (years) 69 (9) 
Weight (kg) 83.8 (15.4) 
Height (cm) 170 (9) 
BMI (kg/m2) 27.6 (7.4) 
Waist Circumference (cm) 134.2 (12.3) 
Duration of Claudication (years) 4 years, 4 months (3 years, 1 month) 
Systolic Blood Pressure (mm/Hg) 134 (12) 
Diastolic Blood Pressure (mm/Hg) 74 (11) 
Previous Lower Limb Surgery no. 1 
ABPI 0.70 (0.14) 
Comorbidities no. (history of) (%) Smoker (current or former) 28 (65%)  
Coronary disease 5 (12%) 
Hypercholesterolaemia 28 (65%) 
Diabetes 5 (12%) 
Current Medication no. (%) Fibrates or statins 34 (79%)  
Anti-diabetic 5 (12%)  
Anti-hypertensive 28 (65%)  
Beta blocker 29 (67%)  
Antiplatelet 42 (98%) 
Other 7 (16%) 
Table 1: Patient Demographics 402 
 403 
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Measure Visit 1 Visit 2 P 
value 
Maximum Treadmill Walking 
Distance (m) 
355 (268) Not Repeated N/A 
WELCHa questionnaire (%) 26 (22) 18 (13) 0.04 
WIQb speed subscore (%) 18.2 (8.1) 17.4 (8.5) <0.001 
WIQb distance subscore (%) 24.5 (9.6) 21.3 (7.9) 0.08 
WIQb total (%) 43.1 (29.1) 38.9 (25.6) 0.45 
SF-36c Physical Functioning 35.7 (9.6) 31.5 (9.8) 0.04 
SF-36c  Role-Physical 36.7 (5.1) 32.2 (9.3) 0.04 
SF-36c  Bodily Pain 39.1 (7.1) 32.3 (5.9) <0.001 
SF-36c  General Health 38.7 (6.1) 31.8 (6.5) <0.001 
SF-36c  Vitality 51.4 (6.9) 47.6 (10.2) 0.04 
SF-36c  Social Functioning 39.7 (6.1) 34.3 (10.9) 0.02 
SF-36c  Role-Emotional 39.8 (3.9) 33.1 (11.4) 0.01 
SF-36c  Emotional Well-Being 47.5 (5.7) 39.4 (9.5) <0.001 
SF-36c  Physical Component 
Summary 
30.5 (6.6) 25.1 (10.4) 0.03 
SF-36c  Mental Component 
Summary 
35.7 (7.5) 29.5 (11.8) 0.03 
a Walking Impairment Questionnaire in PAD, b Walking Impairment Questionnaire,  404 
 c Short Form-36 quality of life Questionnaire 405 
Table 2: Patient Questionnaire-based and Treadmill Measurements 406 
 407 
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FIGURE 408 
Figure 1: Comparison of main community walking measurements between the two walks 409 
